amphetamine has been researched along with alpha-synuclein in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abeliovich, A; Armanini, M; Castillo, PE; Choi-Lundberg, D; Fariñas, I; Ho, WH; Hynes, M; Phillips, H; Rosenthal, A; Ryan, A; Schmitz, Y; Shinsky, N; Sulzer, D; Verdugo, JM | 1 |
| Caron, MG; Cory-Slechta, DA; Di Monte, DA; Federoff, HJ; Gainetdinov, RR; Richfield, EK; Thiruchelvam, MJ; Wuertzer, C | 1 |
| Cabin, DE; Chen, A; Cole, NB; Ellis, CE; Gottschalk, W; Lu, B; McIlwain, KL; Murphy, D; Nussbaum, RL; Orrison, B; Paylor, R; Shimazu, K | 1 |
| Biagioni, F; Busceti, CL; di Poggio, AB; Ferrucci, M; Fornai, F; Giusiani, M; Lazzeri, G; Lenzi, P; Natale, G; Paparelli, A; Ruggieri, S | 1 |
| Chesselet, MF; Fleming, SM; Hutson, CB; Levine, MS; Masliah, E; Rockenstein, E; Salcedo, J | 1 |
| Ebadi, M; Govitrapong, P; Klongpanichapak, S; Phansuwan-Pujito, P | 1 |
| Govitrapong, P; Mukda, S; Vimolratana, O | 1 |
| Govitrapong, P; Phansuwan-Pujito, P; Sae-Ung, K; Uéda, K | 1 |
| Björklund, A; Decressac, M; Lundblad, M; Mattsson, B; Weikop, P | 1 |
| Björklund, T; Brundin, P; Hansen, C; Li, JY; Lundblad, M; Murmu, RP; Petit, GH | 1 |
| Cunha-Oliveira, T; Perfeito, R; Rego, AC | 1 |
| Brekk, OR; Kirik, D; Landeck, N; Papadopoulou-Daifoti, Z; Papasilekas, T; Pitychoutis, PM; Stefanis, L; Xilouri, M | 1 |
| Becker, JP; Butler, B; Davari, P; Goodwin, JS; Khoshbouei, H; Rana, T; Saha, K; Sambo, D | 1 |
| Bellucci, A; Benfenati, F; Björklund, A; Bubacco, L; Faustini, G; Longhena, F; Missale, C; Pizzi, M; Spano, P; Varanita, T | 1 |
1 review(s) available for amphetamine and alpha-synuclein
| Article | Year |
|---|---|
Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Topics: alpha-Synuclein; Amphetamine; Dopaminergic Neurons; Humans; Illicit Drugs; Mitochondria; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Substantia Nigra; Ubiquitin | 2013 |
13 other study(ies) available for amphetamine and alpha-synuclein
| Article | Year |
|---|---|
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.
Topics: alpha-Synuclein; Amphetamine; Animals; Autoreceptors; Calbindins; Calcium; Corpus Striatum; Dopamine; Dopamine Agents; Female; Gene Expression; Glutamic Acid; Hippocampus; Locomotion; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Neurons; Presynaptic Terminals; rab3A GTP-Binding Protein; S100 Calcium Binding Protein G; Substantia Nigra; Synaptic Transmission; Synucleins | 2000 |
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; alpha-Synuclein; Amphetamine; Animals; Behavior, Animal; Brain; Corpus Striatum; Disease Models, Animal; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Genetic Predisposition to Disease; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Transgenic; Motor Activity; Mutagenesis, Site-Directed; Nerve Tissue Proteins; Parkinson Disease; Parkinson Disease, Secondary; Presynaptic Terminals; Promoter Regions, Genetic; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2002 |
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Behavior, Animal; Blotting, Western; Calcium; Cells, Cultured; Crosses, Genetic; Electric Stimulation; Excitatory Postsynaptic Potentials; Heterozygote; Hippocampus; Immunoblotting; Male; Mice; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Neurons; Presynaptic Terminals; Synapses; Synaptic Transmission; Synaptic Vesicles; Synaptosomes; Synucleins | 2002 |
Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Alkanes; alpha-Synuclein; Amides; Amphetamine; Analysis of Variance; Animals; Blotting, Western; Dopamine; Dopamine Uptake Inhibitors; Gene Expression Regulation; Glutamate Decarboxylase; Homovanillic Acid; Immunohistochemistry; Inclusion Bodies; Isoenzymes; Mice; Mice, Inbred C57BL; Microscopy, Electron, Transmission; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Neurons; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2005 |
Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benserazide; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Genetic Predisposition to Disease; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Stereotypic Movement Disorder | 2006 |
Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells.
Topics: alpha-Synuclein; Amphetamine; Antioxidants; Cell Line, Tumor; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Drug Interactions; Electron Transport Complex I; Gene Expression Regulation, Neoplastic; Humans; Melatonin; Neuroblastoma; Phosphorylation; Serine; Tyrosine 3-Monooxygenase | 2008 |
Melatonin attenuates the amphetamine-induced decrease in vesicular monoamine transporter-2 expression in postnatal rat striatum.
Topics: alpha-Synuclein; Amphetamine; Animals; Animals, Newborn; Blotting, Western; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Melatonin; Phosphorylation; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2011 |
Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Brain; Dopamine; Melatonin; Nerve Degeneration; Neuroprotective Agents; Rats; Rats, Wistar | 2012 |
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Behavioral Symptoms; Cell Count; Chromatography, High Pressure Liquid; Dependovirus; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; ELAV Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Humans; Levodopa; Mesencephalon; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regulatory Elements, Transcriptional; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2012 |
A novel α-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of α-synuclein-GFP.
Topics: Aging; alpha-Synuclein; Amphetamine; Animals; Discrimination, Psychological; Dopamine; Dopamine Agents; Dopaminergic Neurons; Green Fluorescent Proteins; Humans; Locomotion; Mice; Mice, Transgenic; Movement Disorders; Neocortex; Nervous System Diseases; Olfaction Disorders; Smell; Substantia Nigra; Ventral Tegmental Area | 2013 |
Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Apomorphine; Autophagy; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Dependovirus; Dopamine; Embryo, Mammalian; Enzyme Inhibitors; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Hemagglutinins; Humans; Lysosomal Membrane Proteins; Lysosomal-Associated Membrane Protein 2; Macrolides; Mice; Molecular Chaperones; Motor Activity; Nerve Degeneration; Neuroblastoma; Neurons; Rats; Transfection; Tyrosine 3-Monooxygenase | 2013 |
Dopamine Transporter Activity Is Modulated by α-Synuclein.
Topics: alpha-Synuclein; Amphetamine; Animals; Biotinylation; Brain; Cell Line; Cell Membrane; CHO Cells; Cricetinae; Cricetulus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Fluorescence Resonance Energy Transfer; Humans; Membrane Microdomains; Neurodegenerative Diseases; Synaptic Transmission; Synucleins | 2015 |
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Amphetamine; Animals; Central Nervous System Stimulants; Dependovirus; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Nerve Degeneration; Neurons; Parkinson Disease; Stereotyped Behavior; Substantia Nigra; Synapses; Synapsins; Vesicle-Associated Membrane Protein 2 | 2018 |